Diagnosis and Treatment of Osteoporosis

Osteoporosis
lege of Physicians. Screening for osteoporosis in men: a clinical practice
guideline from the American College of Physicians [published correction
appears in Ann Intern Med. 2008;148(11):888]. Ann Intern Med.
2008;148(9):680-684.
15. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich
T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation:
a meta-analysis of randomized controlled trials. JAMA.
2005;293(18):2257-2264.
16. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect
of alendronate on risk of fracture in women with existing vertebral
fractures. Fracture Intervention Trial Research Group. Lancet.
1996;348(9041):1535-1541.
17. McClung MR, Geusens P, Miller PD, et al., for the Hip Intervention Program
Study Group. Effect of risedronate on the risk of hip fracture in
elderly women. N Engl J Med. 2001;344(5):333-340.
18. Black DM, Delmas PD, Eastell R, et al., for the HORIZON Pivotal Fracture
Trial. Once-yearly zoledronic acid for treatment of postmenopausal
osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
19. Cauley JA, Robbins J, Chen Z, et al., for the Women’s Health Initiative
Investigators. Effects of estrogen plus progestin on risk of fracture and
bone mineral density: the Women’s Health Initiative randomized trial.
JAMA. 2003;290(13):1729-1738.
20. Chesnut CH III, Skag A, Christiansen C, et al., for the Oral Ibandronate
Osteoporosis Vertebral Fracture Trial in North America and Europe
(BONE). Effects of oral ibandronate administered daily or intermittently
on fracture risk in postmenopausal osteoporosis. J Bone Miner Res.
2004;19(8):1241-1249.
21. Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk
of first vertebral fracture in osteoporotic women. Osteoporos Int.
2002;13(6):501-505.
22. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk
in postmenopausal women with osteoporosis treated with raloxifene:
results from a 3-year randomized clinical trial. Mutiple Outcomes of Raloxifene
Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-645.
23. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of
nasal spray salmon calcitonin in postmenopausal women with established
osteoporosis: the prevent recurrence of osteoporotic fractures
study. PROOF Study Group. Am J Med. 2000;109(4):267-276.
24. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone
(1-34) on fractures and bone mineral density in postmenopausal
women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.
25. U.S. Food and Drug Administration. Drugs @ FDA. http://www.access
data.fda.gov/scripts/cder/drugsatfda/. Accessed December 7, 2008.
26. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J
Med. 2003;348(1):42-49.
27. Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe
BH. Interventions for preventing falls in elderly people. Cochrane Database
Syst Rev. 2003;(4):CD000340.
28. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors
for preventing hip fractures in elderly people: systematic review. BMJ.
2006;332(7541):571-574.
29. Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to
prevent hip fracture in nursing home residents: the HIP PRO randomized
controlled trial. JAMA. 2007;298(4):413-422.
30. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium
supplementation on clinical fracture and bone structure: results of a
5-year, double-blind, placebo-controlled trial in elderly women. Arch
Intern Med. 2006;166(8):869-875.
31. Cranney A, Horsley T, O’Donnell S, et al. Effectivness and safety of vitamin
D in relation to bone health. Evidence report/technology assessment
No. 158. Rockville, Md.: Agency for Healthcare Research and
Quality; August 2007. http://www.ahrq.gov/downloads/pub/evidence/
pdf/vitamind/vitad.pdf. Accessed December 7, 2008.
32. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
33. Marcus R, Wong M, Heath H III, Stock JL. Antiresorptive treatment of
postmenopausal osteoporosis: comparison of study designs and outcomes
in large clinical trials with fracture as an endpoint. Endocr Rev.
2002;23(1):16-37.
34. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative
effectiveness of treatments to prevent fractures in men and
women with low bone density or osteoporosis. Ann Intern Med.
2008;148(3):197-213.
35. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men
with primary and secondary osteoporosis: results of a 1-year study.
Rheumatol Int. 2006;26(5):427-431.
36. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of
osteoporosis in men. N Engl J Med. 2000;343(9):604-610.
37. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate
on bone mineral density and vertebral fracture in patients receiving glucocorticoids:
a randomized, double-blind placebo-controlled extension
trial. Arthritis Rheum. 2001;44(1):202-211.
38. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment
on bone density and vertebral fracture in patients on corticosteroid
therapy. Calcif Tissue Int. 2000;67(4):277-285.
39. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy
and fracture rates in osteoporotic women: relationship to vertebral and
nonvertebral fractures from 2 US claims databases. Mayo Clin Proc.
2006;81(8):1013-1022.
40. Black DM, Schwartz AV, Ensrud KE, et al., for the FLEX Research Group.
Effects of continuing or stopping alendronate after 5 years of treatment:
the Fracture Intervention Trial Long-term Extension (FLEX): a randomized
trial. JAMA. 2006;296(24):2927-2938.
41. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections
in postmenopausal women with osteoporosis: one-year results
from the dosing intravenous administration study. Arthritis Rheum.
2006;54(6):1838-1846.
42. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and
osteonecrosis of the jaws [published correction appears in Ann Intern
Med. 2006;145(3):235]. Ann Intern Med. 2006;144(10):753-761.
43. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic
fracture. Osteoporos Int. 2002;13(11):858-867.
44. Black DM, Bilezikian JP, Ensrud KE, et al., for the PaTH Study Investigators.
One year of alendronate after one year of parathyroid hormone
(1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-565.
45. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower
doses of conjugated equine estrogens with and without medroxyprogesterone
acetate on bone in early postmenopausal women. JAMA.
2002;287(20):2668-2676.
46. Greenspan SL, Resnick NM, Parker RA. Combination therapy
with hormone replacement and alendronate for prevention of
bone loss in elderly women: a randomized controlled trial. JAMA.
2003;289(19):2525-2533.
200 American Family Physician www.aafp.org/afp Volume 79, Number 3 ◆ February 1, 2009